Key result
Novel pathogenic LMNA mutation causes dilated cardiomyopathy with proximal weakness and diffuse paraspinal atrophy.
Why the study?
Laminopathies caused by LMNA gene mutations present with diverse phenotypes, and this report describes a previously undescribed LMNA mutation presenting with cardiomyopathy, paraspinal muscle atrophy, and proximal lower extremity weakness.
Case Report (n=1)
No
Answers are grounded in this paper and cite their sources.
Retrospective review reports a novel LMNA mutation causing cardiomyopathy and paraspinal atrophy in a 56-year-old woman, expanding recognized laminopathy phenotypes.
Objective: To report a previously undescribed LMNA mutation presenting with cardiomyopathy, paraspinal muscle atrophy and proximal lower extremity weakness. Background: Laminopathies are disorders caused by mutations in the LMNA gene and present with diverse phenotypes, including limb girdle muscular dystrophy type 1B, Emery Dreyfuss muscular dystrophy, dilated cardiomyopathy, Charcot Marie Tooth type 2 (CMT2B1), amongst others. Design/Methods: Retrospective review of medical records and mutational analysis report. Results: A 56-year-old woman with a history of non-ischemic cardiomyopathy was referred to the neuromuscular clinic due to paraspinal atrophy noted in lumbar MRI. She had a history of cardiac arrest at age 44, atrial fibrillation, dilated cardiomyopathy requiring pacemaker and defibrillator with latest left ventricular ejection fraction at 30–35%. She reported progressive lower extremity weakness with difficulty climbing stairs, getting off the floor, since age 52. Examination was significant for mild neck flexor, hamstrings and hip flexor weakness (R/L) 4-/4 (MRC scale). Sensory examination and reflexes were normal. There were no contractures noted. She was unable to squat or to get out of chair without pushing off. Lumbosacral spine MRI obtained for low back pain showed moderate to severe posterior paraspinal muscles and gluteus maximus atrophy. Cervical and thoracic spine CT showed diffuse paraspinal muscular atrophy. Creatine kinase and aldolase were normal. EMG demonstrated myopathic motor units in tensor fascia latae muscle. Genetic testing identified a heterozygous variant in the LMNA gene c.792_793ins? (p.Lys265Alafs*9), classified as pathogenic. This variant is likely the result of insertion of a mobile element into exon 4 of this gene and is expected to cause loss-of-function. Conclusions: We report a novel LMNA mutation presenting diffuse paraspinal muscle atrophy, dilated cardiomyopathy and proximal lower extremity weakness. The identification of disease associated mutations and their phenotypes will be helpful in the better understating of the disease. Disclosure: Dr. Villafuerte Trisolini has nothing to disclose. Drew Cratsenberg has nothing to disclose. The institution of Douglas Stoller has received research support from Amgen. Jason Helvey has nothing to disclose. The institution of Dr. Fernandes has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. The institution of Dr. Fernandes has received research support from Mallinckrodt Inc. The institution of Dr. Fernandes has received research support from MGH philanthropy .
No takes yet. Share an insight, caveat, or question.
Trisolini et al. (2021) conducted a case report in Laminopathy presenting with dilated cardiomyopathy, paraspinal muscle atrophy, and proximal lower extremity weakness (n=1). LMNA mutation c.792_793ins? (p.Lys265Alafs*9) was evaluated on Clinical and genetic characterization of novel LMNA variant phenotype. A novel pathogenic LMNA mutation (c.792_793ins?) presented in a 56-year-old woman with dilated cardiomyopathy, diffuse paraspinal atrophy, and proximal weakness.
Synapse has enriched 10 related papers. Consider them for comparative context: